Gsk (GSK) Income from Non-Controlling Interests (2009 - 2026)

Gsk (GSK) has 18 years of Income from Non-Controlling Interests data on file, last reported at $3.2 billion in Q3 2026.

• For the quarter ending Q3 2026, Income from Non-Controlling Interests changed N/A year-over-year to $3.2 billion; the trailing twelve-month figure through Sep 2026 stood at $14.8 billion (changed N/A YoY), and the FY2025 full-year result was $8.4 billion, up 121.77% from the prior year.
• Income from Non-Controlling Interests was $3.2 billion for Q3 2026 at Gsk, up from $741.9 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $18.3 billion in Q4 2022 to a low of $84.5 million in Q3 2024.
• A 5-year average of $4.1 billion and a median of $2.2 billion in 2025 frame the typical range for Income from Non-Controlling Interests.
• Across the five-year window, Income from Non-Controlling Interests plunged 95.65% in 2024 and surged 3325.55% in 2025, its largest moves.
• Gsk's Income from Non-Controlling Interests stood at $18.3 billion in 2022, then sank by 64.04% to $6.6 billion in 2023, then tumbled by 42.51% to $3.8 billion in 2024, then surged by 120.86% to $8.4 billion in 2025, then tumbled by 61.61% to $3.2 billion in 2026.
• Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $3.2 billion in Q3 2026, $741.9 million in Q2 2026, and $2.5 billion in Q1 2026.